Document is current

Article History

Received: 23 October 2021

Accepted: 14 March 2022

First Online: 27 March 2022

Declarations

:

: Patients included in this study underwent genetic counselling and signed written informed consent for their data and samples to be used for research purposes. The Ethics Committee at Heidelberg University had no objections against this study (project identification codes 065/2001 and S-426/2017).

: Not applicable.

: E.G., C.A.E. and K.H. report an issued patent “Gene panel specific for pulmonary hypertension and its uses” European Patent ID: EP3507380. Z.S., M.S., D.C., M.Le. and J.K. declare that they have no competing interests related to this study. P.X. has received personal fees from MSD and OMT outside the submitted work. N.B. received speaker fees from Actelion pharmaceuticals / Janssen Medical, Bayer HealthCare and MSD, outside the submitted work. BE received travel fees, con-sulting fees, speaking fees, and/or honoraria from Actelion, MSD, Bayer and OMT, outside the submitted work. H.A.G. received consulting fees and or payment or honoraria for lectures from Actelion, Janssen, Bayer, MSD, Acceleron, Gossamer Bio, Novartis, Pfizer outside the submitted work. H.K. reports grants from GSK and Actelion and personal fees from Pfizer, GSK, Bayer, United Therapeutics, Actelion and Jansen outside the submitted work. H.G. reports personal fees from Actelion, AstraZeneca, Bayer, BMS, GSK, Janssen-Cilag, Lilly, MSD, Novartis, OMT, Pfizer, and United Therapeutics outside the submitted work. H.J.S. reports consulting fees from Actelion/Janssen and speaker fees for Actelion, Bayer, GSK, Janssen and MSD outside the submitted work. K.M. reports personal speaker honoraria from Janssen, MSD, GSK outside the submitted work. K.M.O. received fees for lectures and/or consultations from Acceleron, Actelion, Bayer, GSK, Janssen, MSD, Pfizer and United Therapeutics outside the submitted work. M.La. received con-sultancy or lecture honoraria from Actelion, Bayer, BRAHMS – Thermo Fisher Scientific, Daiichi-Sankyo, MSD and Bristol-Myers Squibb-Pfizer outside the submitted work. M.H. has re-ceived personal fees for consultations and lectures from Acceleron, Actelion, AstraZeneca, Bayer, BerlinChemie, GSK, Janssen-Cilag, MSD, and Novartis, outside the publication. M.M.H. has re-ceived fees for consultations and/or lecturers from Acceleron, Actelion, Bayer, GSK, Janssen, MSD and Pfizer, all outside the submitted work. N.S. received honoraria for presentations from Actelion outside the submitted work. R.E. received honoraria for lectures from GSK, United Therapeutics, OMT, Janssen, outside the submitted work. S.H. received honoraria for lectures, consultancy, or both from Actelion, AOP, Bayer/MSD, GSK, Novartis, OMT, Pfizer, and United Therapeutics out-side the submitted work. S.R. has received honoraria for lectures, consultancy, or both from Ac-tavis, Actelion, Bayer, GSK, Lilly, Novartis, Pfizer, and United Therapeutics outside the submitted work. T.L. received consulting fees from Acceleron Pharma, Actelion/Janssen-Cilag, Bayer, GSK, MSD and personal honoraria for lectures from Actelion/Janssen-Cilag, BMS, MSD, Pfizer outside the submitted work. EG has received grants and personal fees from Actelion, Bayer AG, and MSD; grants from GSK, Novartis, and United Therapeutics and personal fees from SCOPE, OrPha Swiss GmbH, and Zurich Heart House, outside the submitted work. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results.